Drug-induced myopathies.
Two major entities continue to be controversial in the field of clinical myotoxicity: the various myopathies that are induced by the cholesterol-lowering agents and the acute quadriplegic myopathy of intensive care. Both conditions are relatively common, but their pathogenesis is unclear. The problematic issues related to these disorders are presented, with suggested topics for future research.
Argov
Z
Z
Department of Neurology, Hadassah University Hospital and the Hebrew University-Hadassah Medical School, Jerusalem, Israel. zargov@md2.huji.ac.il
D000208:Acute Disease; D000924:Anticholesteremic Agents / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects; D009135:Muscular Diseases / Q000139:chemically induced*; D009466:Neuromuscular Blocking Agents / Q000009:adverse effects; D011782:Quadriplegia / Q000139:chemically induced / Q000503:physiopathology; D013256:Steroids / Q000009:adverse effects
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009466:Neuromuscular Blocking Agents; D013256:Steroids